Steminent Biotherapeutics Presents Promising Phase II Results from Taiwan-Japan Study Showing Stable and Positive Clinical Outcomes

On April 23, Steminent Biotherapeutics publicly presented Phase II clinical trial results of its stem cell therapy candidate Stemchymal® for spinocerebellar ataxia (SCA), a form of cerebellar atrophy, at the World Orphan Drug Congress (WODC) in the United States. The data showed that Stemchymal® demonstrated clear disease-modifying effects across multiple clinical evaluation scales, indicating the therapy’s potential to become a new treatment opportunity for patients with cerebellar atrophy.